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Abstract 
Background 
LHON is LEBER's hereditary optic neuroretinopathy with bilateral acute or subacute loss of 
central vision due to optic atrophy. It is linked to point mutations of mitochondrial DNA. 
Mitochondrial DNA (mtDNA) is a small circular molecule of 16,5 kB, which encodes the 
enzymes of the respiratory chain in mitochondria. It is inherited maternally. The most 
common pathogenic mtDNK point mutations associated with LHON are 3460 G→A, 11778 
G→A and 14484 T→C. These mutations are linked with the defects of subunits of complex I 
(NADH-dehydrogenase-ubiquinone reductase) in mitochondria. The 11778 G→A point 
mutation has the worst optic outcome (blindness).  
Methods 
Complete ophthalmologic examination including best corrected visual acuity on the both eyes 
according to Snellen chart, ophthalmoscopy, Goldmann perimetry and colour vision with 
Ishichara plates were done. mtDNA point mutation 11778 G→A was detected in DNA of 
peripheral blood lymphocytes using PCR and RFLP method. 
Results  
This is the first study of Croatian patients with LHON defect associated with mtDNK 
mutations. Two LHON 11778 G→A families are presented in this paper. The mothers and 
female relatives are LHON mutants without symtoms, while the sons mutants suffered from 
blindness. 
Conclusions 
Molecular diagnosis may help in explanation of the cause of LHON disease. LHON should 
not be based solely on clinical description 
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Introduction 
 
Mitochondria are organelles responsible for energy production by respiratory chain, 
oxidative degradation of carbon substrates into water and oxygen. These reaction are 
catalysed by respiratory chain complexes I, II, III, IV imbedded in the inner membrane of the 
mitochondria. The mitochondrial genome is 16569 bp long. It contains double stranded DNA 
molecule and no introns. It replicates independently of the nuclear genome. Mitochondrial 
DNA is maternally inherited (3, 4, 17 Zeviani, Bauer, Chinnery). The defects of 
mitochondrial DNA are large scale rearrangements with single deletions or more rarely 
duplications. Over 118 point mutations of mitochondrial DNA are known today (16Van W) 
and are associated with different clinical phenotypes (3, 4, 17 Zeviani, Bauer, Chinnery).  
Leber's hereditary optic neuroretinopathy (LHON) has been linked to nearly 20 different point 
mutations of mitochondrial DNA (14, 17 Zeviani, Torroni). The most common pathogenic 
point mutations named primary are 3460 G→A 11778 G→A 14484 T→C. Point mutation 
3460 G→A is associated with the defect of ND1 subunit of complex I (6Huoponen), 11778 
G→A  with the defect of ND4 subunit of complex I (16 Wallace), while 14484 T→C with the 
defect of ND6 subunit of complex I (7, 8  Johns). LHON was first linked to point mutations of 
mitochondrial DNA in 1988 (16 Wallace 1988). Clinically, LHON is manifested with 
bilateral acute or subacute loss of central vision due to optic atrophy. The typical funduscopic 
finding in the acute stage of the disease is a peripapillary microangiopathy. The visual defect 
is usually the only clinical feature. However, it can be occasionally associated with cardiac 
conduction abnormalities (pre-excitation syndrome), peripheral neuropathy and/or ataxia (3, 
4, 17 Zeviani, Chinnery). Usually, the onset of the disease is in the second and third decade, 
with male predominance (17 Zeviani). The average onset of the disease among males is 24.3 
years, while among females 31.3 years (Leo-Kottler 10). However, there is a case report about 
a 6 year old girl with LHON (2 Balayre). Point mutation 11778 G→A has poor prognosis for 
vision, while 14484 T→C is linked to mild course of the disease (4, 17 Zeviani, Chinerry). A 
multiple sclerosis has been described in some female patients with point mutation 11778 
G→A. In multiple sclerosis investigation for oligoclonal bands in cerebrospinal fluid (CSF), 
evoked potentials and MR brain scan can be supplemented with mitochondrial diagnosis (13 
Olsen NK). Association between mitochondrial DNA point mutation 11778 G→A  with 
demylenating disease as a marked female predominance has been reported (5 Flaningan KM). 
Spontaneous recovery from LHON has been described in 5 out of 136 patients (7, Johns).  
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 This work represents the first study of Croatian families with LHON using molecular 
diagnosis. DNA from peripheral blood lymphocytes was tested, as a more convenient tissue, 
than muscle or skin fibroblasts.  
 
Materials and methods 
 
Patients 
23 pateints from five families were included in this study. Loss of vision was the criteria for 
LHON testing. Maternal line of inheritance was used for testing the relatives. DNA analysis 
was done by consent of patients and their relatives. 
 
Ophthalmologic examinations 
A complete ophthalmologic examination was performed for patients with visual impairment: 
1. Best corrected visual acuity using Snellen charts 
2. Colour vision was tested with Ishichara plates  
3. Ophthalmoscopy  
4. Goldmanns kinetic and/or automated perimetry  
 
DNA testing from peripheral blood lymphocytes using PCR-RFLP method 
There is no LHON specific laboratory findings except DNA analysis. DNA was isolated from 
peripheral blood lymphocytes (11 Miller SA). PCR reaction was performed for each point 
mutations separately using specific set of primers for each point mutation. The position of 
primers in the sequence of the mitochondrial genome (1 Anderson) was for 3460 G→A point 
mutation fw 5’3150 and 3’3600 rv, for 11778 G→A point mutation fw 5’11680 and rv 3’ 
12000 and for 14484 T→C fw 5’14450 and rv 3’ 14608. PCR reaction was performed using 
the PCR Core Kit (Roche, Germany). PCR products  were verified on 1.5% agarose gels. 
Specific PCR reaction was followed by RFLP (restriction lenght fragment polymorphism) 
method. PCR products were digested overnight at 37oC with restrictive enzymes, for each 
point mutation a specific restrictive enzyme was used: BsaH1 for 3460, SfaN1 for 11778 (17 
Wallace) and Mbo for 14484 (Johns 8) (Bio Labs, New England). Restrictive fragments were 
tested on 1.5 % agarose gel using ethidium-bromide for UV visualisation of DNA (17 Zeviani 
M). Positive mutant DNA was included as control in testings. 
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Results 
mtDNA point mutation 11778 G→A was detected in ten DNA samples out of twenty 
three tested. Point mutations 3460 G→A and 14484 T→C were not found in any of DNA 
samples tested. 2 LHON family cases are presented in this paper (Figure 1, Figure 2). The 
diagnosis of other patients was neuroopticopathia. 
 
Family case No. 1.  
The 4 persons positive for LHON 11778 G→A mitochondrial point mutations are 
family members, two female cousins (aged 50 and 53), their two sons (aged 27 and 25) 
(Figure 1). The mothers were LHON mutants, with no LHON symptoms. However, their sons 
are both 11778 G→A mutants, with visual acuity 0.01 blindness.  
The male patient (26 years old) was hospitalized firstly on the Neurological clinic, 
Osijek, because of unilateral loss of the right eye vision and papiloedema. Laboratory testing 
showed no pathological values, CAT scan and MRI with and without contrast was performed 
and revealed no intracranial process but only sferoidal and ethmoidal sinusitis of the right 
side. He was transferred to the Ophthalmology Department, Clinical Hospital Osijek. A 
month later from the onset of the disease he lost the other eye vision. Ophthalmoscopy 
revealed teleangiectatic microangiopathy in carrier and nerve fiber layer swelling 
(papiloedema). Goldmans kinetic perimetry revealed centroceal scotoma in affected person. 
As he already had a male cousin in second degree, who suffered from sudden visual loss of 
both eyes few years ago, connected through maternal inheritance line (their mothers were 
cousins) he was suspected for LHON disease. Indeed, DNA testing turned to be LHON 
positive for 11778G→A mitochondrial point mutation for him, his cousin and their mothers. 
A month later from the onset of the disease he lost the other eye vision. His male cousin was 
diagnosed LHON 11778G→A at the  age of 17, also lost both eyesight having visual acuity 
0.01.  
 
Family case No. 2. 
Six persons LHON 11778 G→A mutants are family members: a young men, his mother, 
sister, the mother's sister and her daughter and grand-daughter (Figures 2, 3). The male patient 
(26 years old) was hospitalized on the Department of Ophthalmology, Clinical Hospital 
Center Zagreb due to unilateral visual loss on the right eye and papiloedema. Two months 
later he had loss of vision on the left eye. Best corrected visual acuity on the both eyes was 
0.08 according to Snellen chart and ophthalmoscopy revealed papilloedema. Goldmann 
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perimetry showed the presence of central scotomatas with absence of inner isopters. 
Laboratory testing showed no pathological values. CAT scan revealed no intracranial process. 
Pulse steroid therapy was administrated. Since there was no satisfactory recovery of visual 
function, we suspected to LHON disease. In next several years he was hospitalized both on 
Department of Ophthalmology, as well on Department of Neurology due to deterioation of 
vision, where he was administrated pulse steroid therapy. Despite of therapy, on the last 
ophthalmological examination best corrected visual acuity is 0.08 according to Snellen charts, 
ophthalmoscopy reveals temporal palor of optic disc. Automated Octopus perimetry showed 
general depression with the presence of central scotomatas. DNA testing turned to be positive 
for LHON 11778G→A mitochondrial point mutation. His sister, mother, mother's sister-aunt,  
her daughter and grandaughter were also LHON 11778G→A mutants, but without visual 
impairement.  
 
Discussion 
This work is the first Croatian pilot study of LHON linked to mitochondrial DNA 
point mutations. The most common three mitochondrial DNA point mutations associated with 
LHON 3460 G→A, 11778 G→A and 14484 T→C were tested in twenty three patients with 
LHON symptoms. Mitochondrial DNA point mutation LHON 11778 G→A was detected in 
ten patients, four and six in two different families. In this study, the onset of the disease was 
in one patient at the age of 16, in his cousin at the age of 26, and in the third patient at the age 
of 26. These data are in line with literature about the onset of LHON in young males (4, 16, 
17 Wallace, Zeviani, Chinnery). LHON 11778 G→A has poor diagnosis, these young men 
almost completely lost their eyesight bilaterally (17 Zeviani). The mothers and female 
relatives were LHON 11778 G→A mutants, carriers, having no clinical symptoms (17 
Zeviani). These findings are in-line with literature data about male predominance of the the 
clinically manifested disease. 
  The other patients tested were negative for these three most common LHON mutations 
and were diagnosed as neuroopticopathia. However, LHON may not be completely excluded, 
since over 20 mtDNA point mutations linked to LHON have been described in the literature 
untill now (17 Zeviani, 4 Chinnery).  
Identification of the disease should not be based solely on clinical description, because 
it may be an entity other than LHON in some individuals or even in entire pedigrees. Adjunct 
tests apart from genetic analysis (9, 12) generally are of a limited value in the evaluation of 
LHON. 
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 Molecular diagnosis accurately explains the cause of LEBER'S optical defect as 
maternally inherited mtDNK point mutation. The role of genetic counseling in this disease 
should not be underestimated either (9 Kjer, 12 Nikoskelainen). LHON prognosis is better for 
females,  mutants without symptoms. 
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Figure 1. 
Presentation of a LHON 11778 G→A family No. 1 
 
Legend 
Female, not tested 
Male, not tested 
LHON mutant, tested, mother without clinical symptoms 
LHON mutant, tested, son without clinical symptoms 
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Figure 2. 
 
Presentation of the LHON 11778 G→A family No. 2 
 
 
Legend 
Female, not tested 
Male, not tested 
LHON carrier, female tested 
LHON mutant, tested, son 
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 Figure 3. 
 
DNA testing of the LHON family with mitochondrial DNA point mutation 11778 G→A. 
RFLP analysis in 1.5% agarose gel  is presented. 
 
    1                2              3              4               5              6 
 
 
 
 
Lane 1. DNA standard 
Lane 2. patient,  LHON mutant 11778 G→A (no restriction, 320 bp) 
Lane 3. the mutant's mother,  LHON  mutant 11778 G→A 
Lane 4. the mutant's aunt (mother's sister), LHON mutant 11778 G→A 
Lane 5. positive control, LHON mutant 11778 G→A 
Lane 6. negative control (two restriction fragments 222 and 98 bp) 
 
← 320 bp 
← 222 bp 
←  98 bp 
